Source:http://linkedlifedata.com/resource/pubmed/id/19567351
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2009-7-1
|
| pubmed:abstractText |
This prospective study evaluated the frequency and severity of respiratory symptoms during the second respiratory syncytial virus (RSV) season in an italian cohort of preterm infants (< or = 35 weeks) who had received palivizumab prophylaxis in their first year of life (October 2004-April 2005) and who had not previously been hospitalized for RSV-induced lower respiratory tract infection (LRTI). infants were evaluated at enrolment (May-September 2005), in October/November 2005 and in April 2006. The occurrence of any respiratory episode, the rate of hospitalization for respiratory-related LRTI, total length of stay in hospital, physician-documented recurrent wheezing (>or = 3 physician-documented episodes of wheezing) and use of airway medication/antibiotics were recorded during follow-up. All infants had prior palivizumab prophylaxis during their first RSV season. In the total evaluable population (n=260), 32.3% of infants experienced at least one respiratory episode, 3.8% required short hospitalization because of LRTI, 8.5% had physician-documented recurrent wheezing, and 48.8% required airway medications/antibiotics during follow-up. in this study the rate of airway morbidity, hospitalization and physician-documented recurrent wheezing during the second RSV season was low among preterm infants who had received prior palivizumab prophylaxis.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
1973-9478
|
| pubmed:author |
pubmed-author:BareraGG,
pubmed-author:BenincoriNN,
pubmed-author:BragettiPP,
pubmed-author:CitroGG,
pubmed-author:DI Luzio PaparattiUU,
pubmed-author:FanosVV,
pubmed-author:GallinaM RMR,
pubmed-author:GalliniFF,
pubmed-author:GuidaGG,
pubmed-author:MerollaRR,
pubmed-author:PudduMM,
pubmed-author:QuartulliLL,
pubmed-author:RomanoG VGV,
pubmed-author:RossiG AGA,
pubmed-author:ScarcellaAA,
pubmed-author:SilvestriMM,
pubmed-author:TuminelliFF,
pubmed-author:ViaL DallaLD
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
21
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
302-10
|
| pubmed:dateRevised |
2011-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:19567351-Antibodies, Monoclonal,
pubmed-meshheading:19567351-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:19567351-Cohort Studies,
pubmed-meshheading:19567351-Female,
pubmed-meshheading:19567351-Follow-Up Studies,
pubmed-meshheading:19567351-Hospitalization,
pubmed-meshheading:19567351-Humans,
pubmed-meshheading:19567351-Infant,
pubmed-meshheading:19567351-Infant, Newborn,
pubmed-meshheading:19567351-Infant, Premature,
pubmed-meshheading:19567351-Male,
pubmed-meshheading:19567351-Prospective Studies,
pubmed-meshheading:19567351-Respiratory Sounds,
pubmed-meshheading:19567351-Respiratory Syncytial Virus Infections,
pubmed-meshheading:19567351-Respiratory Tract Diseases,
pubmed-meshheading:19567351-Respiratory Tract Infections
|
| pubmed:year |
2009
|
| pubmed:articleTitle |
Respiratory disorders and hospitalization rates during the second RSV season in preterm infants who received palivizumab prophylaxis during their first RSV season.
|
| pubmed:affiliation |
Neonatal Intensive Care Unit, University of Cagliari, Cagliari, Italy.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|